Revision 1

#97318 Store at -20C

PhosphoPlus® TrkA (Tyr490)/TrkB (Tyr516) Antibody Duet

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

UniProt ID: #P04629

Entrez-Gene Id: 4914

Product Includes	Product #	Quantity	Mol. Wt.	Isotype/Source
Phospho-TrkA (Tyr490)/TrkB (Tyr516) (C35G9) Rabbit mAb	4619	100 µl	140 kDa	Rabbit IgG
Trk (pan) (A7H6R) Rabbit mAb	92991	100 µl	120-140 kDa	Rabbit IgG

Please visit cellsignal.com for individual component applications, species cross-reactivity, dilutions, protocols, and additional product information.

Description

PhosphoPlus® Duets from Cell Signaling Technology (CST) provide a means to assess protein activation status. Each Duet contains an activation-state and total protein antibody to your target of interest. These antibodies have been selected from CST's product offering based upon superior performance in specified applications.

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. *Do not aliquot the antibody*.

Background

The family of Trk receptor tyrosine kinases consists of TrkA, TrkB, and TrkC. While the sequence of these family members is highly conserved, they are activated by different neurotrophins: TrkA by NGF, TrkB by BDNF or NT4, and TrkC by NT3 (1). Neurotrophin signaling through these receptors regulates a number of physiological processes, such as cell survival, proliferation, neural development, and axon and dendrite growth and patterning (1). In the adult nervous system, the Trk receptors regulate synaptic strength and plasticity. TrkA regulates proliferation and is important for development and maturation of the nervous system (2). Phosphorylation at Tyr490 is required for Shc association and activation of the Ras-MAP kinase cascade (3,4). Residues Tyr674/675 lie within the catalytic domain, and phosphorylation at these sites reflects TrkA kinase activity (3-6). Point mutations, deletions, and chromosomal rearrangements (chimeras) cause ligand-independent receptor dimerization and activation of TrkA (7-10). TrkA is activated in many malignancies including breast, ovarian, prostate, and thyroid carcinomas (8-13). Research studies suggest that expression of TrkA in neuroblastomas may be a good prognostic marker as TrkA signals growth arrest and differentiation of cells originating from the neural crest (10).

The phosphorylation sites are conserved between TrkA and TrkB: Tyr490 of TrkA corresponds to Tyr512 in TrkB, and Tyr674/675 of TrkA to Tyr706/707 in TrkB of the human sequence (14). TrkB is overexpressed in tumors, such as neuroblastoma, prostate adenocarcinoma, and pancreatic ductal adenocarcinoma (15). Research studies have shown that in neuroblastomas, overexpression of TrkB correlates with an unfavorable disease outcome when autocrine loops signaling tumor survival are potentiated by additional overexpression of brain-derived neurotrophic factor (BDNF) (16-18). An alternatively spliced truncated TrkB isoform lacking the kinase domain is overexpressed in Wilms' tumors and this isoform may act as a dominant-negative regulator of TrkB signaling (17).

Background References

1. Huang, E.J. and Reichardt, L.F. (2003) *Annu Rev Biochem* 72, 609-42.
2. Segal, R.A. and Greenberg, M.E. (1996) *Annu Rev Neurosci* 19, 463-89.
3. Stephens, R.M. et al. (1994) *Neuron* 12, 691-705.
4. Marsh, H.N. et al. (2003) *J Cell Biol* 163, 999-1010.
5. Obermeier, A. et al. (1993) *EMBO J* 12, 933-41.
6. Obermeier, A. et al. (1994) *EMBO J* 13, 1585-90.
7. Arevalo, J.C. et al. (2001) *Oncogene* 20, 1229-34.
8. Reuther, G.W. et al. (2000) *Mol Cell Biol* 20, 8655-66.
9. Greco, A. et al. (1997) *Genes Chromosomes Cancer* 19, 112-23.
10. Pierotti, M.A. and Greco, A. (2006) *Cancer Lett* 232, 90-8.
11. Lagadec, C. et al. (2009) *Oncogene* 28, 1960-70.
12. Greco, A. et al. (2010) *Mol Cell Endocrinol* 321, 44-9.
13. Ødegaard, E. et al. (2007) *Hum Pathol* 38, 140-6.
14. Huang, E.J. and Reichardt, L.F. (2003) *Annu Rev Biochem* 72, 609-42.

15. Geiger, T.R. and Peeper, D.S. (2005) *Cancer Res* 65, 7033-6.
16. Han, L. et al. (2007) *Med Hypotheses* 68, 407-9.
17. Aoyama, M. et al. (2001) *Cancer Lett* 164, 51-60.
18. Desmet, C.J. and Peeper, D.S. (2006) *Cell Mol Life Sci* 63, 755-9.

Trademarks and Patents

Limited Uses